Thematics Asset Management Buys 15,487 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Thematics Asset Management significantly increased its stake in IQVIA Holdings Inc. by 3,991.5% through the purchase of 15,487 shares, bringing their total holdings to 15,875 shares valued at approximately $2.8 million.
• Several institutional investors, including American National Bank & Trust and Clal Insurance Enterprises Holdings Ltd, have also made notable acquisitions in IQVIA during the same quarter, showcasing a growing interest in the company.
• Analysts have recently raised the price targets for IQVIA, with Mizuho increasing its target from $190 to $225, contributing to a consensus rating of "Moderate Buy" with a target price of $228.62.

Thematics Asset Management lifted its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 3,991.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 15,875 shares of the medical research company's stock after acquiring an additional 15,487 shares during the period. Thematics Asset Management's holdings in IQVIA were worth $2,799,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in IQV. American National Bank & Trust purchased a new position in IQVIA during the 1st quarter valued at about $26,000. Clal Insurance Enterprises Holdings Ltd increased its stake in shares of IQVIA by 436.7% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after acquiring an additional 131 shares during the last quarter. Golden State Wealth Management LLC raised its holdings in shares of IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after acquiring an additional 130 shares in the last quarter. AllSquare Wealth Management LLC acquired a new stake in IQVIA during the first quarter valued at $33,000. Finally, ST Germain D J Co. Inc. grew its stake in IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after purchasing an additional 76 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Stock Performance

NYSE:IQV traded down $0.07 during trading hours on Thursday, hitting $188.73. 1,161,570 shares of the company traded hands, compared to its average volume of 1,323,966. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $252.88. The firm has a 50-day moving average of $176.32 and a 200 day moving average of $167.99. The stock has a market capitalization of $32.08 billion, a price-to-earnings ratio of 18.14, a P/E/G ratio of 2.07 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion for the quarter, compared to the consensus estimate of $3.96 billion. During the same quarter in the previous year, the firm posted $2.64 EPS. The business's revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Insider Buying and Selling

In other news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares of the company's stock, valued at $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. JPMorgan Chase & Co. reduced their price target on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a report on Monday, May 19th. Barclays lifted their target price on shares of IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 23rd. Evercore ISI increased their price target on shares of IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 9th. Mizuho raised their price target on shares of IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a report on Friday, July 25th. Finally, UBS Group upped their price objective on shares of IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $228.62.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.